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Abstract
Background: Our objective was to assess the predictive value of the changes of liver stiffness (LS) for clinical
outcome in HIV/HCV-coinfected patients with compensated liver cirrhosis and a LS value < 40 kPa.
Methods: Prospective cohort of 275 HIV/HCV-coinfected patients with cirrhosis, no previous liver decompensation
(LD) and LS < 40 kPa. The time from diagnosis to LD and/or hepatocellular carcinoma (HCC) and the predictors of this
outcome were evaluated. Significant progression of LS was defined as an increase≥ 30 % over the baseline value at
any time during the follow-up.
Results: After a median (Q1-Q3) follow-up of 32 (20–48) months, 19 (6.9 %, 95 % CI: 3.8 %–9.9 %) patients developed a
first LD and/or HCC. At the end of the follow-up, 247 (90 %) patients had undergone a further LS examination. Of
them, 77 (31 %) patients had a significant progression of LS. The mean (SD) survival time free of LD and/or HCC
was 67 (3) and 77 (1) months in patients with or without significant progression of LS (p = 0.01). Significant
progression of LS was an independent predictor of LD and/or HCC (Adjusted Hazard Ratio 4.63; 95 % confidence
interval: 1.34–16.02; p = 0.015).
Conclusions: Significant progression of LS is associated with a higher risk of clinical events in HIV/HCV-coinfected
patients with compensated cirrhosis and LS < 40 kPa.
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Background
Liver stiffness (LS), assessed by transient elastography
(TE), is a surrogate marker of portal hypertension (PH)
in patients with end-stage liver disease (ESLD). Thus,
several studies have demonstrated that LS correlates
with the hepatic venous pressure gradient, an invasive
measure of the portal pressure [1–3]. Besides, the pres-
ence of oesophageal varices (EV), a major complication
of PH, can be predicted by LS [4–8]. TE is painless,
non-invasive and can be easily performed in outpatient
setting, which has contributed to widespread use of this
procedure.
In the recent years, several investigations have con-
firmed that LS may also provide prognostic information in
patients with ESLD. Thus, a prospective cohort study con-
ducted in 239 human immunodeficiency virus (HIV)/
hepatitis C virus (HCV)-coinfected patients with a new
diagnosis of cirrhosis demonstrated that LS values at
diagnosis predict the clinical outcome in these individ-
uals [9]. In that study, a LS ≥ 40 kiloPascals (kPa) at the
date of the diagnosis of cirrhosis was an independent
predictor of the emergence of liver decompensation
(LD) in this population [9].
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New direct-acting antiviral agents against HCV have
notably increased the rates of sustained virological re-
sponse (SVR) in HCV-infected patients, including those
who are coinfected with HIV and those harbouring ad-
vanced liver disease. However, patients with established
ESLD are a unique scenario where efficacy rates might
be slightly lower and the clinical benefit of the achieve-
ment of SVR less marked. For these reasons, the predic-
tion of clinical events is still critical in the management
of ESLD. In this sense, some clinical decisions, as the in-
dication of liver transplantation, are based on the risk of
developing LD or death. In clinical practice, this predic-
tion is commonly made on the basis of clinical and rou-
tine biochemical parameters, which are combined in
prognostic scores as the Child-Turcotte-Pugh (CTP) [10]
or the Model for the End-Stage Liver Disease (MELD)
scores [11], and, less commonly, on the basis of the inva-
sive measurement of portal pressure. As stated above, a
value of LS ≥ 40 kPa at the time of diagnosis of cirrhosis
adds additional prognostic information to that provided
by CTP or MELD scores. However, high-risk patients, as
those harbouring elavated values of LS, would probably
benefit less from therapeutic and preventive measures.
For these reasons, clinical investigation should focus on
implementing the prediction of events in those individ-
uals with intermediate or low risk, i.e. patients with LS
values < 40 kPa, which represent three quarters of the
overall HIV/HCV-coinfected cirrhotic patient popula-
tion [9]. In this sense, we hypothesized that the changes
of LS over time may have an impact on the clinical out-
come of patients with ESLD.
The objective of our study was to assess the predictive
value of the changes of LS for clinical outcome in HIV/
HCV-coinfected patients with compensated liver cirrho-
sis and a LS value < 40 kPa.
Patients and methods
Study design and patients
This was an analysis of the prospective HEPAVIR cir-
rhosis cohort, in which patients from 7 hospitals in
Andalusia, Southern Spain are recruited. This prospect-
ive cohort of HIV/HCV-coinfected patients with com-
pensated liver cirrhosis was created in February 2006.
From this date, all consecutive HIV/HCV-coinfected
patients with detectable serum HCV-RNA and a new
diagnosis of liver cirrhosis, based on the presence of
LS > 14 kPa [12], and no evidence of toxic, metabolic or
autoimmune liver disease, were enrolled, provided that
they had not developed a LD before entering the cohort.
For this study, those patients who had a LS < 40 kPa at the
time of the diagnosis of cirrhosis were selected. Subjects
who presented with a LD or hepatocellular carcinoma
(HCC) at the time of cirrhosis diagnosis were excluded.
Follow-up
Patients were evaluated at least every 6 months, includ-
ing an assessment of LD and the performance of rou-
tine laboratory tests. TE examinations were performed
by a single experienced operator in each center follow-
ing a standardized technique [13]. After the initial LS
measurement, periodic TE examinations were performed
usually every 12 months, according to the caring physician
criteria and the availability in each center.
The management of ESLD in the cohort was performed
as previously reported [9]. LD, which included portal
hypertensive gastrointestinal bleeding (PHGB), ascites,
hepatorenal syndrome (HRS), spontaneous bacterial peri-
tonitis (SBP) and hepatic encephalopathy (HE), and HCC
were diagnosed and managed according to criteria stated
elsewhere [14–16]. Therapy against HCV was offered dur-
ing follow-up according to the physician criteria, usually
following guidelines in force during the follow-up or ex-
pert opinions [17].
Patients were prospectively seen until death, liver trans-
plant or the censoring date (30 November 2012). Vital sta-
tus and causes of death were recorded according to
clinical records. Patients lost to the follow-up or their next
of kin were contacted via telephone whenever possible.
Statistical analysis
Comparisons of continuous variables were made using
the Student t test or the Mann–Whitney U test, depend-
ing on the normality of distributions. The Wilcoxon test
was used to compare values of continuous variables at
different time-points. The chi-square and the Fisher
tests were used for comparisons of categorical variables.
The primary end-point of the study was the emergence
of a first episode of LD and/or HCC. The relationship
between the time to the emergence of the primary end-
point and variables that could potentially be associated,
which included baseline LS and changes of LS during
follow-up, were analysed.
For survival analyses, we considered the baseline time-
point the date of the first TE examination in which the
diagnosis of cirrhosis was established. The time-to-event
was computed as the months elapsed from baseline to
the emergence of the primary outcome. Kaplan-Meier
estimates of the cumulative probability of survival were
compared using the log-tank test. For these analyses
continuous variables were categorized according to the
median value or cut-off points considered to be clinically
relevant. Baseline LS was also categorized by clinically
relevant cut-off points based on previous studies. The
definition of significant progression was developed after
the performance of exploratory analyses. Thus, different
analytic approaches were explored and that with the bet-
ter performance was chosen. Consequently, significant
progression of LS was defined as an increment of LS at
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any time during the follow-up ≥ 30 % over the baseline
LS. According to this, patients were divided in progres-
sors, those who showed a significant progression of LS,
and non-progressors, the rest of the population. Those
variables with a p value ≤ 0.1 on the univariate analysis
were entered in time-dependent Cox proportional haz-
ard models, which also included age, sex and the
achievement of SVR during follow-up. Finally, the pres-
ence of statistical interactions were evaluated by means
of multivariate Cox regression analyses. Associations
with a p <0.05 were considered significant in the multi-
variate analysis. The hazard ratio (HR) and the respect-
ive 95 % confidence interval (CI) were calculated.
Comparisons between the areas under the receptor op-
erating characteristic (AUROC) curves were performed
using the Hanley and McNeil test. The statistical analysis
was carried out using the SPSS 22 Statistical Software
Package (SPSS; Chicago, Illinois, USA) and the STATA
version 9 (Stata Corp LP, College Station, TX, USA).
Ethical aspects
The study was designed and conducted following the
Helsinki declaration. The Ethics committee of the Hospital
Universitario de Valme approved the study. All the partici-




Three hundred and forty-nine HIV/HCV-coinfected pa-
tients with a diagnosis of cirrhosis on the basis of a LS ≥
14 kPa and who fulfilled inclusion criteria had been re-
cruited in the HEPAVIR cohort until November 2012.
Of them, 275 (79 %) patients had a baseline LS < 40 kPa
and were selected for this study. The main characteris-
tics of the study population are summarized in Table 1.
During follow-up, 107 (39 %) patients started therapy
against HCV. At the end of study period, 13 out of these
107 patients were still receiving such a therapy. SVR was
achieved in 29 (31 %) of the remaining 94 patients.
LD and mortality
The median (Q1-Q3) follow-up was 32 (20–48) months.
Fourteen (5 %) patients were lost to follow-up. Nineteen
(6.9 %, 95 % CI: 3.8 %–9.9 %) patients developed a first
LD and/or HCC as the first cirrhosis complication
during the follow-up. The incidence rate of LD and/or
HCC was 4.6 per 100 person-years (95 % CI: 2.9 %–
7.3 %). Ascites was the most common type of first LD,
appearing in 10 (53 %) patients. PHGB occurred in 2
(10 %) patients and SBP in 1 (5 %). HCC was the first
hepatic event in 6 (32 %) patients. The median (Q1-
Q3) time to the development of a LD and/or HCC was
17 (11–28) months.
Twenty-two (7.6 %, 95 % CI: 4.4 %–10.7 %) patients
died during follow-up. The mortality rate was 4.1 deaths
per 100 person-years (95 % CI: 2.6–6.1). In 12 patients,
death was related with liver failure. Thus, the liver-
related mortality rate was 3.2 deaths per 100 person-
years (95 % CI: 1.8–5.6). Specific liver-related causes of
death were: 3 patients died due to HE, 2 due to PHGB, 1
due to HRS, 1 due to SBP and 5 due HCC. Ten patients
died because of non-liver related causes: 3 patients due
to cerebral bleeding, 2 patients as a result of a non-
AIDS related neoplasm, 2 patients due to bacteriemic
pneumococcal pneumonia, 1 patient owing to Pneumo-
cystis jirovecii pneumonia, 1 patient due to acute renal
failure other than HRS and 1 patient committed suicide.
Of these 10 patients who died because of non-liver re-
lated causes, only 1 had previously developed a LD. No
patient underwent a liver transplant.
Table 1 Characteristics of the study population (n = 275)
Parameter Value
Age (years)a 44 (42–48)
Male gender, no. (%) 245 (89)
Daily alcohol intake > 50 grs/day, no. (%) 40 (14)
Previous intravenous drug users, no. (%) 250 (91)
Previous therapy against HCV, no (%) 57 (21)





HCV RNA load (log10 IU/mL)
a,c 6.17 (5.68–6.69)
Positive hepatitis B virus surface antigen,
no (%)
8 (3)
Serum alanine aminotransferase (IU/L)a 74 (48–105)
Serum aspartate aminotransferase (IU/L)a 72 (47–104)
Total bilirrubin (mg/dL)a 0.7 (0.5–1.02)
Platelet count (/mm3)a 130000
(94000–171750)
HIV RNA load < 50 copies/mL, no. (%) 184 (67)
CD4 cells/mLa 459 (265–626)
ARTd, no (%) 256 (83)
MELDe scorea,f 7 (6–9)
Child-Turcotte-Pugh class, no (%)
A 248 (90)
B 27 (10)
Liver stiffness (kPa)a 20 (17–27)
aMedian (Q1-Q3)
Available in b269 and
c254 patients
dART: Antiretroviral therapy
eMELD: Model for end-stage liver disease
fAvailable in 251 patients
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Association between baseline LS and the emergence of
hepatic events
Higher baseline LS values tended to be associated with
developing a first LD and/or HCC (Table 2 and Fig. 1a).
The probabilities of remaining free of LD and/or HCC
at 1 year, 2 years, 3 years and 4 years were 99, 97, 94
and 94 %, respectively, for patients with a baseline LS < 21
kPa whereas they were 97, 93, 89 and 87 % for patients
with a baseline LS ≥ 21 kPa. Comparisons between groups
using different cut-off points of baseline LS did not yield
statistically significant results. Thus, the respective figures
for patients with baseline LS < 30 kPa were 99, 95, 91 and
91 %, whereas for those with a baseline LS ≥ 30 kPa were
96, 96, 93 and 89 %, respectively.
Changes of LS during follow-up and association with the
emergence of hepatic events
At the end of the follow-up, 247 (90 %) patients had
undergone at least one LS examination after that car-
ried out at screening for entering the cohort. Twelve
(4 %) patients were included in the cohort in the last
12 months before the censoring date and had only a LS
determination at baseline. Two patients (1 %) were lost
to the follow-up before a second examination could be
performed. In the remaining 14 patients (5 %), a second
LS examination was not available. In 120 (44 %) pa-
tients, 4 or more LS examinations were performed. One
hundred and forty (57 %) patients underwent LS examina-
tions every 6 months. The median (Q1-Q3) LS at baseline
Table 2 Univariate associations between emergence of and episode of hepatic decompensation and/or HCC and other parameters
(n = 275)
Parameter Category No. (%) with decompensation P Bivariate (Log rank test)
Sex Male 16 (6)
Female 3 (10) 0.4
Age < 44 years 6 (5)
≥ 44 years 13 (8) 0.2
Hepatitis B virus surface antigen Negative 17 (6)
Positive 2 (25) 0.15
HCV genotype 1–4 13 (6)
2–3 6 (9) 0.4
HCV RNA load (log10 IU/mL)
a < 6.7 13 (7)
≥ 6.7 5 (8) 0.5
Therapy against HCV during follow-up No therapy or therapy without SVRb 16 (6)
SVRb 3 (11) 0.6
CD4 cell count (cells/mm3) < 200 5 (8)
≥ 200 14 (6) 0.5
Platelet count (/mm3) < 150.000 16 (9)
≥ 150.000 3 (3) 0.061
APRIc score < 1.5 9 (7)
≥ 1.5 10 (7) 0.9
Child-Turcotte-Pugh class A 15 (6)
B 4 (15) 0.002
MELDd scoree < 14 17 (7)
≥ 14 0 (0) 0.6
Liver stiffness (kPa) < 21 7 (5)
≥ 21 12 (9) 0.18
Progression of liver stiffness ≥ 30 % from baselinef No 5 (3)
Yes 10 (13) 0.011
aAvailable in 254 patients
bSVR: Sustained virological response
cAPRI: AST platelet ratio index
dModel for end-stage liver disease
eAvailable in 251 patients
fEvaluable in 247 patients
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and at the end of the follow-up was 20 (17–27) kPa and
19 (13–28) kPa, respectively (p = 0.3). Figure 2 shows the
distribution of patients in different groups according to
the evolution of LS from baseline to the end of follow-up
in the 247 patients who underwent a LS examination at
the end of the follow-up. LS increased from baseline to
the end of the study period in 107 (43 %) patients.
Seventy-seven (31 %) patients showed an increase of
LS ≥ 30 % from baseline at any time during the follow-
up. The occurrence of progression ≥ 30 % of LS at any
time during the follow-up was associated with the emer-
gence of a LD and/or HCC (Table 2 and Fig. 1b). The
mean (standard deviation [SD]) survival time free of LD
and/or HCC was 67 (3) and 77 (1) months in those pa-
tients with or without an increase ≥ 30 % in LS during
the follow-up, respectively (p = 0.01). The probabilities of
remaining free of LD and/or HCC at 1 year, 2 years,
3 years and 4 years were 99, 97, 96 and 96 %, respect-
ively, for patients without a significant progression of LS
during the follow-up whereas they were 97, 93, 88 and
86 % for patients in whom LS increased ≥ 30 % from
baseline at any time during the follow-up. Significant
progression of LS occurred before the emergence of LD
and/or HCC in the 10 patients who developed this event
during follow-up and had a significant progression of
LS. Thus, the median (Q1-Q3) elapsed time from LS
progression to LD was 6 (4–13) months.
Independent predictors of the emergence of LD and/or
HCC
In order to compare the predictive value of baseline LS
and progression of LS for clinical outcomes, two multi-
variate models were generated: one included baseline LS
and another progression of LS during the follow-up. For
the latter, we previously explored if progression of LS
covariated with time in a time-dependent Cox model,
and we were able to rule it out. Table 3 summarizes
these analyses. In the multivariate model that included
baseline LS, age, sex, previous therapy against HCV and
CTP stage were independently associated with develop-
ing a LD and/or HCC (Table 3). Baseline LS was not in-
dependently associated with the primary end-point. In
the multivariate model that included progression of LS,
the independent predictors of developing a LD and/or
HCC were age, previous therapy against HCV, consecu-
tion of SVR during follow-up, CTP stage and progres-
sion of LS ≥ 30 % at any time during the follow-up
(Table 3).
Additionally, we compared the ability of baseline LS
and progression of LS during follow-up to predict the
Fig. 1 Liver stiffness and probability of liver-related events during follow-up. a Probability of remaining free of developing a hepatic decompensation
and/or hepatocellular carcinoma according to baseline liver stiffness. LS, liver stiffness. kPa, KiloPascals. b Probability of remaining free of developing a
hepatic decompensation and/or hepatocellular carcinoma according to the evolution of liver stiffness during the follow-up. Progressors are defined as
those patients showing an increase of LS≥ 30 % over the baseline value at any time during the follow-up
Fig. 2 Distribution of patients according to the evolution of liver
stiffness from baseline to the end of follow-up in the 247 patients
who underwent a liver stiffness examination at the end of
the follow-up
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primary outcome. Thus, we computed the respective
AUROC of the multivariate models including either base-
line LS or progression of LS, obtaining a higher AUROC
for the progression of LS-based model. Namely, the
AUROC (95 % CI) for baseline LS including multivariate
model was 0.609 (0.471–0.748), while the respective figure
for progression of LS including multivariate model was
0.680 (0.541–0.818) (p = 0.1).
Discussion
This study demonstrates that progression of LS is asso-
ciated with the emergence of LD and/or HCC in HIV/
HCV-coinfected patients with ESLD and LS < 40 kPa.
Although the risk of LD was globally low in the short
and mid-term in this population, patients with a signifi-
cant progression of LS during follow-up, as defined in
this study, had a higher risk of clinical events in the
years after the diagnosis of cirrhosis. Besides, this asso-
ciation was independent of other prognostic factors as
CTP score in multivariate analyses. Finally, changes in
LS during the follow-up have a stronger impact on the
outcome than the initial value of LS, suggesting that pre-
diction of events should be based on changes in LS rather
than on a single value in patients with a LS < 40 kPa.
It has been demonstrated that LS values at diagnosis
of cirrhosis predict clinical outcome in patients with
ESLD in different settings [9, 18–23]. However, the
clinical meaning of LS changes and its influence in the
prognosis of cirrhotic patients is less well-established.
In a French study [24], which included 150 patients
with primary biliary cirrhosis who underwent at least 2
TE examinations, LS progression was associated with a
composite end-point including LD, liver transplant and
death of any cause. However, this study included pa-
tients with different stages of liver fibrosis, with only
8 % of them having cirrhosis according to baseline LS
values. Un updated analysis of the previous cohort
showing similar results has been very recently reported
[25]. A second study [22], conducted in 103 Asian pa-
tients with hepatitis B virus chronic infection undergoing
antiviral therapy with F3 or F4 fibrosis, has reported that
early changes in LS, defined as those occurring in the first
6 months of follow-up, were associated with a composite
end-point of LD, HCC and liver-related death.
In our opinion, the present study has several methodo-
logical advantages that solve some of the questions
raised by the above-mentioned studies [22, 24, 25]. First,
it includes patients with cirrhosis exclusively, all of them
diagnosed by the same method, TE. Second, we have ex-
cluded those patients harbouring a LS ≥ 40 kPa, in order
to avoid potential confusions due to the strong impact
that high baseline LS can exert on the outcome. Third,
we have performed comparisons between the prognostic
value of baseline LS and the changes of LS that suggest
a superior performance of the latter. Finally, the criteria
used in this study for defining significant progression of
LS was chosen after performing different exploratory
sensitivity analyses looking for that with the best per-
formance, as there are not enough studies so far that
have established a “consensus definition”. After that, we
classified patients according to the occurrence of an in-
crease ≥ 30 % over the baseline value at any time during
the follow-up for several reasons. First, it is a high cut-
off value, which excludes potential changes of LS due to
Table 3 Multivariate models for the prediction of hepatic decompensation and/or HCC
Parameter Multivariate hazard ratio (95 % CI) P multivariate
Model 1
Age (years)a 1.11 (1.01–1.16) 0.028
Female sex 3.2 (0.59–17.16) 0.177
SVRb during follow-up 0.46 (0.12–1.81) 0.266
Platelet count (/mm3) ≥ 150.000 4.01 (0.81–19.85) 0.089
Child-Turcotte-Pugh class A 1.49 (0.18–12.41) 0.713
Baseline liver stiffness≥ 21 kPa 1.9 (0.59–6.07) 0.279
Model 2
Age (years)a 1.06 (0.99–1.13) 0.053
Female sex 2.36 (0.46–12.09) 0.302
SVRb during follow-up 0.26 (0.06–1.14) 0.075
Platelet count (/mm3) ≥ 150.000 2.99 (0.61–14.77) 0.178
Child-Turcotte-Pugh class A 1.88 (0.23–15.55) 0.556
Progression of liver stiffness ≥ 30 % from baseline 4.63 (1.34–16.02) 0.015
aConsidered as a continuous variable for multivariate analyses
bSVR: Sustained virological response. Model 1 indicates the multivariate model based on baseline liver stiffness. Model 2 indicates the multivariate model based
on the progression of liver stiffness
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normal variability in measures between examinations.
Second, it takes into account the initial value of LS,
which modulates the impact of the changes by consider-
ing also the risk level from what the patient starts. Third,
it was the analytic approach that performed the best.
Our results contribute to the growing evidence that fa-
vours the routine clinical application of LS measurement
in the management of patients with ESLD. Studies have
shown that mild PH can be predicted based on routine
clinical data and the evaluation of LS [26, 27]. Besides,
the presence of EV requiring therapy can be excluded on
the basis of the assessment of LS [4–8]. Notably, the risk
of HCC development varies according to the pattern of
changes in LS values and serial measurements of LS
have been proposed as a monitoring tool for estimating
the risk of HCC development in patients chronically in-
fected by hepatitis B virus [28]. Finally, PH-related
complications can be predicted by TE. LS values at the
diagnosis of cirrhosis predict clinical outcome and
identify a group of patients at a high risk for decom-
pensation in the short term, those harbouring a LS ≥ 40
kPa [9]. As shown in this study, significant progression
of LS may also help to detect early an increased risk for
LD and/or HCC in otherwise asymptomatic individuals
with a LS < 40 kPa.
The prediction of clinical events is of a paramount im-
portance in the management of patients with ESLD.
Thus, some decisions, as the indication of liver trans-
plantation, are based on the risk of developing LD or
death. Besides, the allocation of candidates for trans-
plantation in the waiting list in most liver transplant
programs is based on classical prognostic scores as the
MELD score [11]. However, overall prognosis is very
poor in patients with decompensated cirrhosis in certain
populations, as HIV/HCV-coinfected patients [29]. For
this reason, an accurate prediction of complications
should be made early in the course of ESLD in order to
optimize measures. In this sense, we have previously
demonstrated that a LS ≥ 40 kPa provides additional
prognostic information to that given by the CTP or the
MELD score in HIV/HCV-coinfected patients with com-
pensated cirrhosis [9]. The present study confirms that
LS also adds prognostic information to that provided
by classical scores in patients with LS < 40 kPa. To
note, LS changes predict more accurately the risk of
hepatic events than baseline LS and anticipate the de-
velopment of clinical events. In fact, LS progression oc-
curred several months before the emergence LD in our
study. Consequently, sequential measurements of LS
may be considered as a strategy to monitor the risk of
events in this population, as it has also been proposed
by others [30].
Our study may have some limitations. First, LS mea-
surements during follow-up were performed according
to the caring physician criteria and the availability at
each hospital. However, the great majority of patients
were monitored at a minimum every 12 months and
more than one half of the patients were monitored every
6 months. We cannot completely exclude that more fre-
quent LS monitoring would have identified changes that
may have been not detected with this interval, although
this seems very unlikely. Besides, the interval between
examinations was quite similar in another studies asses-
sing this issue [24, 25]. Second, the number of events
was relatively low and the follow-up period somewhat
short for a low-risk population. This might have pre-
cluded us to identify some independent associations in
multivariate analysis and might have influenced the
performance of the multivariate models. However, even
with this potential limitation, this study has been able
to prove that the progression of LS is an independent
predictor of clinical events and that adds prognostic in-
formation beyond that provided by the baseline LS
value and CTP score. On the other hand, we present
data from a large, prospective cohort of HIV/HCV-
coinfected patients with compensated cirrhosis diag-
nosed using the same method. Besides, we used a defin-
ition of progression of LS that was strict and easy to
apply in the routine daily practise, while the primary
end-point in our study was the emergence of LD and/
or HCC, which we assessed after a median follow-up of
2.6 years. These are strengths of our study.
Conclusions
In summary, significant progression of LS is associated
with a higher risk of clinical events in HIV/HCV-coin-
fected patients with compensated cirrhosis and a LS < 40
kPa. Besides, changes in LS provide additional prognostic
information to that given by classical prognostic scores, as
CTP or MELD scores. Finally, in this overall low-risk
population, the prediction of clinical events should be
based ideally on the changes of LS better that on a single
LS measurement. Thus, sequential monitoring of LS in
compensated cirrhotic patients is desirable in order to
properly assess the prognosis.
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